Background/Aim. The purpose of this paper is to present the results of esophageal scintigraphy (ES) in achalasia treated by balloon dilatation (BD) for a long period of time between years 1997 and 2016 and to set parameters suitable for prediction of treatment outcomes. Methods. Two-phase ES in anterior projection was performed. The first phase involved swallowing 10 ml of water with 18.5 MBq 99m Tc in supine position. The second phase was performed in standing position after swallowing 100 ml of water. Retention index (RI) of esophageal radioactivity was calculated after the imaging using registered esophageal and gastric counts. ES was performed in 52 patients (34 male and 18 female, aged 22-75 years, median patient age of 44 years) before and after BD. In 32 patients only two scintigraphies were performed. In remaining 20 patients follow-up and repeated scintigraphies were continued including the patients with therapeutic failure and repeated BD. BD was repeated in 8 patients and those were followed up and evaluated over time.Modified BD was performed with Rigiflex balloon dilators. Results. Typical scintigraphic finding in supine position was passive esophageal filling without evidence of motility and in most of patients (43) absent radionuclide elimination to stomach (83%). Evaluating values before and longer after the first BD it has been shown that certain values of RI indicate remission or relapse of disease. The RI difference more than 50% after BD was a reliable indicator of longer remission The age and gender of patients had no impact on dilatation outcome but younger patients were with higher risk of early failure (6 patients during first year after BD). ES showed that the first BD was successful initially in 50 patients and after follow-up in 42 patients (81%). Conclusion. Two-phase supine/standing esophageal scintigraphy is most suitable for diagnosing and follow-up of achalasia.Retention index represents an important parameter for evaluation and prediction of therapeutic response. The RI difference more than 50% after BD is a reliable predictor of longer remission. Age and gender have no impact on dilatation outcome but patients younger than 40 years are with higher risk of early therapeutic failure.